TY - JOUR T1 - BCG protects against COVID-19? A word of caution JF - medRxiv DO - 10.1101/2020.04.09.20056903 SP - 2020.04.09.20056903 AU - Reka Szigeti AU - Domos Kellermayer AU - Richard Kellermayer Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/11/2020.04.09.20056903.abstract N2 - The COVID-19 pandemic, caused by type 2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2), puts all of us to the test. Epidemiologic observations could critically aid the development of protective measures to combat this devastating viral outbreak. A recent publication, linked nation based universal Bacillus Calmette-Guerin (BCG) vaccination to potential protection against morbidity and mortality from SARS-CoV-2, and received much attention in public media, even before its peer review. We wished to validate the findings by examining the association between daily rates of COVID-19 case fatality (i.e. Death Per Case) /Days of the endemic [dpc/d]) and the presence of universal BCG vaccination before 1980, or the year of the establishment of universal vaccination. There was no significant association in either analysis. In this work we emphasize caution amidst the publication surge on COVID-19, and highlight the political/economical-, arbitrary selection-, and fear/anxiety related biases, which may obscure scientific rigor. It is underscored that physical (social) distancing (i.e. quarantine) and use of personal protective equipment (PPE) are the only epidemiologic measures (Iceland being a great example, where universal BCG vaccination policy was never in place), which consistently associate with successful counteraction of morbidity and mortality during the pandemic.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are publicly available https://www.cdc.gov/coronavirus/2019-ncov/about/index.html https://www.niaid.nih.gov/diseases-conditions/coronaviruses https://www.worldometers.info/coronavirus/ https://www.nbcnews.com/science/science-news/scientists-under-pressure-try-balance-speed-safety-coronavirus-vaccine-research-n1168946 https://www.cnn.com/2020/04/01/europe/iceland-testing-coronavirus-intl/index.html https://journals.lww.com/ajg/Documents/COVID19_Han_et_al_AJG_Preproof.pdf https://about.unimelb.edu.au/newsroom/news/2020/march/preventative-vaccine-trial-for-covid-19-healthcare-workers https://ourworldindata.org/coronavirus https://www.socscistatistics.com/tests/spearman/default2.aspx https://www.latimes.com/world-nation/story/2020-04-04/north-koreas-official-coronavirus-count-zero-why-that-claim-is-hard-to-believe ER -